MET Tyrosine Kinase Inhibitor Crizotinib (PF-02341066) Shows Differential Antitumor Effects in Non-small Cell Lung Cancer According to MET Alterations

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

Brian Druker, Moshe Talpaz, Debra Resta et al. · New England Journal of Medicine · 2001 · 5.2K citations · Full text

Medicine, Oncology, Pharmacology +12

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge et al. · New England Journal of Medicine · 2010 · 4.5K citations

Medicine, Oncology, Pharmacology +14

Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function

Lin Chen, Simon N. Willis, Andrew H. Wei et al. · Molecular Cell · 2005 · 1.8K citations · Full text

Life Sciences, Cell Biology, Molecular Biology +13

<i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

Jussi Koivunen, Craig H. Mermel, Kreshnik Zejnullahu et al. · Clinical Cancer Research · 2008 · 983 citations · Full text

Medicine, Oncology, Pharmacology +17

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic<i>EGFR</i>Mutations

Lecia V. Sequist, Renato Martins, David R. Spigel et al. · Journal of Clinical Oncology · 2008 · 834 citations · Full text

Medicine, Oncology, Pharmacology +17